IMVT — Immunovant Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Immunovant Inc

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$35.56
Market Cap$5.89B
Float77.0M
Shares Outstanding203.5M
vs. Analyst Target+13.3% to analyst PT
Dividend RateNone
Analyst Target Price$40.29 (14 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$66.4M -$21,000 -$65.6M
2021 N/A -$107M -$998,000 -$108M
2022 N/A -$157M -$1.2M -$156M
2023 N/A -$211M -$1.3M -$208M
2024 N/A -$259M -$231,000 -$270M
2025 N/A -$414M -$377,000 -$438M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Mar 2025 $160,000 -$106M
Jun 2025 N/A -$121M
Sep 2025 N/A -$127M
Dec 2025 N/A -$111M

Ownership & Float

Insider Ownership57.3%
Institutional Ownership55.9%
Short Float24.1%
% of All Funds Holding2.40%
Number of Funds Holding197

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$27.29Near-term / short-term trend
Weekly40-Week SMA$23.66Medium-term trend
Weekly80-Week SMA$21.55Cyclical trend (business cycle)
Weekly200-Week SMA$22.95Secular trend (multi-year)
Monthly10-Month SMA$24.63Near-term monthly trend
Monthly20-Month SMA$22.55Medium-term monthly trend
Monthly40-Month SMA$25.26Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$27.30 support 1.08x 0 months ago
$16.20 support 1.34x 6 months ago

Historical Earnings Reactions (27 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -1.73% -0.38% 40.74% 2.81% -25.07%
1 Day -2.76% -1.09% 37.04% 11.98% -37.99%
1 Week -1.61% 0.06% 51.85% 28.31% -31.20%
2 Weeks 0.21% 0.27% 59.26% 41.78% -34.98%
1 Month -0.07% 0.81% 51.85% 43.63% -42.38%

Next earnings: June 4, 2026 (14 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.19% 48.5% 326
Tuesday -0.03% 48.2% 359
Wednesday 0.18% 48.5% 355
Thursday 0.33% 48.4% 347
Friday 0.14% 47.4% 348

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 55.9%

Insider Transactions — Smart Summary

Total insider ownership: 57.3%

12-Month Insider Activity Summary

Total Filings24
Net Value-$6.0M
Net Shares Change16,545,368
% of Float21.5%
C-Suite Filings20
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
Roivant Sciences Ltd. +$350M 1 1 buy
Venker Eric Chief Executive Officer -$3.4M 1 1 sell
Girao Tiago Chief Financial Officer -$763,011.2 1 N/A
Fromkin Andrew J. -$517,189.13 1 N/A
Van Tuyl Christopher Chief Legal Officer -$419,189.097 2 N/A
Hughes Douglas J. -$348,666 1 N/A
Stout Jay S Chief Technology Officer -$251,577.56 1 N/A
Gloria Melanie Chief Operating Officer -$216,567.26 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-11-21 – 2025-12-03 3 3 -$1.2M 1 C-suite
2026-04-10 – 2026-04-24 5 4 -$1.4M 5 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-04-03 Venker Eric Chief Executive Officer -$3.4M Transaction at $21.22, now +67.6%
2025-12-12 Roivant Sciences Ltd. +$350M Transaction at $21.00, now +69.3%
2026-04-24 Girao Tiago Chief Financial Officer -$763,011.2 Transaction at $29.62, now +20.1%
2026-05-01 Susman Robert Graham -$67,979.34 Transaction at $27.17, now +30.9%
2025-12-03 Hughes Douglas J. -$348,666 Transaction at $23.24, now +53.0%
2025-12-03 Fromkin Andrew J. -$517,189.13 Transaction at $23.25, now +53.0%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Immunovant Inc (IMVT) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for IMVT on Trend Edge →